Objective: To report on a cohort of patients with incidental prostate cancer (IPC) that was treated by an active surveillance (AS) protocol in the HAROW study. Materials and Methods: The HAROW study is an observational study on the management of localized prostate cancer in Germany. Treating urologists were reporting clinical parameters, information on therapy and clinical course of disease at 6-month intervals. Results: In total, 3,169 patients were enrolled. In 224 patients were found an IPC and 104 (46%) of them were put on an AS protocol. The mean follow-up was 26.5 months. Tumor progression was noted in 16 patients. In 11 patients, AS was replaced by a definite intervention. In univariate and multivariate analyses, only PSA density correlated with progression. Conclusion: This is the first prospective description of an IPC patient cohort on AS as part of an outcomes research study. AS was selected as a therapeutic strategy in nearly half of the patients (46%). Only a minor proportion (16%) displayed progression. Of the clinical parameters, only PSA density correlated with progression.

Keywords:
Active surveillance, Incidental prostate cancer, Outcomes research, T1a prostate cancer, T1b prostate cancer
1.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds): American Joint Committee on Cancer Staging Manual, ed 7. New York, Springer, 2010.
2.
Jones JS, Follis HW, Johnson JR: Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis 2009;12:57-60.
3.
Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, Pummer K, Hubmer G: Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 2003;62:451-455.
4.
Melchior S, Hadaschik B, Thüroff S, Thomas C, Gillitzer R, Thüroff J: Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int 2009;103:1478-1481.
5.
Lowe BA, Listrom MB: Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988;140:1340-1344.
6.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-137.
7.
Herden J, Ernstmann N, Schnell D, Weißbach L: The HAROW study: an example of outcomes research: a prospective, non-interventional study comparing treatment options in localized prostate cancer. Urologe A 2014;53:1743-1752.
8.
Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A: A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:380-385.
9.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
10.
Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ: Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013;63:597-603.
11.
Pfaff H: Health care research: the last mile in sight. Dtsch Med Wochenschr 2006;131:1488-1490.
12.
Scriba PC: Health services research - physicians' competence. Dtsch Med Wochenschr 2005;130:1577-1578.
14.
Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS: Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-983.
16.
Fujita K, Landis P, McNeil BK, Pavlovich CP: Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664-2669.
17.
Lee DH, Chung DY, Lee KS, Kim IK, Rha KH, Choi YD, Chung BH, Hong SJ, Kim JH: Clinical experiences of incidental prostate cancer after transurethral resection of prostate (TURP) according to initial treatment: a study of a Korean high volume center. Yonsei Med J 2014;55:78-83.
18.
Ahmad S, O'Kelly F, Manecksha RP, Cullen IM, Flynn RJ, McDermott TE, Grainger R, Thornhill JA: Survival after incidental prostate cancer diagnosis at transurethral resection of prostate: 10-year outcomes. Ir J Med Sci 2012;181:27-31.
19.
Masue N, Deguchi T, Nakano M, Ehara H, Uno H, Takahashi Y: Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b. Int J Urol 2005;12:1045-1049.
20.
Descazeaud A, Peyromaure M, Salin A, Amsellem-Ouazana D, Flam T, Viellefond A, Debré B, Zerbib M: Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. Eur Urol 2008;53:355-361.
21.
Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (eds): American Joint Committee on Cancer Staging Manual for Staging of Cancer, ed 4. Philadelphia, PA, Lippincott, 1992.
22.
Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC: Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 1981;125:516-520.
23.
Fan K, Peng CF: Predicting the probability of bone metastasis through histological grading of prostate carcinoma: a retrospective correlative analysis of 81 autopsy cases with antemortem transurethral resection specimen. J Urol 1983;130:708-711.
24.
Humphrey P, Vollmer RT: The ratio of prostate chips with cancer: a new measure of tumor extent and its relationship to grade and prognosis. Hum Pathol 1988;19:411-418.
25.
Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F: Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol 2008;54:118-125.
26.
Magheli A, Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML: Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy. J Urol 2007;178:1277-1280.
27.
Rajab R, Fisher G, Kattan MW, Foster CS, Møller H, Oliver T, Reuter V, Scardino PT, Cuzick J, Berney DM; Transatlantic Prostate Group: An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent. Mod Pathol 2011;24:58-63.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.